CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice - PubMed (original) (raw)
Comparative Study
. 1998 Nov 1;161(9):4463-6.
Affiliations
- PMID: 9794366
Comparative Study
CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice
M J McCluskie et al. J Immunol. 1998.
Abstract
Mucosal immunity is difficult to induce with subunit vaccines unless such vaccines are administered with a mucosal adjuvant such as cholera toxin (CT); however, CT is toxic in humans. Synthetic oligodeoxynucleotides containing immunostimulatory CpG motifs (CpG) are potent adjuvants for the induction of Th1-like systemic immune responses against parenterally delivered proteins. Here, we show in mice that intranasal delivery of hepatitis B surface Ag, which alone has no effect, elicits good immune responses when given with CpG oligodeoxynucleotides and/or CT. Overall, CpG is superior to CT for the induction of humoral and cell-mediated systemic immunity as well as mucosal immune responses (IgA) at local (lung) and distant (feces) sites. Furthermore, CpG and CT act synergistically, giving stronger responses than those observed with 10 times more of either adjuvant alone. Ab isotypes were predominantly IgG1 (Th2-like) with CT, mixed IgG1/IgG2a (Th0) with CpG, and predominantly IgG2a (Th1-like) with CpG and CT together.
Similar articles
- Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen.
Mutwiri G, Benjamin P, Soita H, Babiuk LA. Mutwiri G, et al. Vaccine. 2008 May 23;26(22):2680-8. doi: 10.1016/j.vaccine.2008.03.031. Epub 2008 Apr 3. Vaccine. 2008. PMID: 18430493 - Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles.
Borges O, Cordeiro-da-Silva A, Tavares J, Santarém N, de Sousa A, Borchard G, Junginger HE. Borges O, et al. Eur J Pharm Biopharm. 2008 Jun;69(2):405-16. doi: 10.1016/j.ejpb.2008.01.019. Epub 2008 Jan 31. Eur J Pharm Biopharm. 2008. PMID: 18364251 - Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA.
McCluskie MJ, Weeratna RD, Payette PJ, Davis HL. McCluskie MJ, et al. FEMS Immunol Med Microbiol. 2002 Feb 18;32(3):179-85. doi: 10.1111/j.1574-695X.2002.tb00551.x. FEMS Immunol Med Microbiol. 2002. PMID: 11934561 - Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
Holmgren J, Adamsson J, Anjuère F, Clemens J, Czerkinsky C, Eriksson K, Flach CF, George-Chandy A, Harandi AM, Lebens M, Lehner T, Lindblad M, Nygren E, Raghavan S, Sanchez J, Stanford M, Sun JB, Svennerholm AM, Tengvall S. Holmgren J, et al. Immunol Lett. 2005 Mar 15;97(2):181-8. doi: 10.1016/j.imlet.2004.11.009. Epub 2004 Dec 7. Immunol Lett. 2005. PMID: 15752556 Review. - The role of CpG dinucleotides in DNA vaccines.
Krieg AM, Yi AK, Schorr J, Davis HL. Krieg AM, et al. Trends Microbiol. 1998 Jan;6(1):23-7. doi: 10.1016/S0966-842X(97)01145-1. Trends Microbiol. 1998. PMID: 9481820 Review.
Cited by
- Adjuvants for COVID-19 Vaccines.
Castrodeza-Sanz J, Sanz-Muñoz I, Eiros JM. Castrodeza-Sanz J, et al. Vaccines (Basel). 2023 Apr 26;11(5):902. doi: 10.3390/vaccines11050902. Vaccines (Basel). 2023. PMID: 37243006 Free PMC article. Review. - Immune response induced by recombinant pres2/S-protein and a pres2-S-protein fused with a core 18-27 antigen fragment of hepatitis B virus compared to conventional HBV vaccine.
Parizad EG, Imani Fooladi AA, Sedighian H, Behzadi E, Amani J, Khosravi A. Parizad EG, et al. Virus Genes. 2023 Aug;59(4):499-514. doi: 10.1007/s11262-023-01995-z. Epub 2023 May 4. Virus Genes. 2023. PMID: 37140777 - New-age vaccine adjuvants, their development, and future perspective.
Verma SK, Mahajan P, Singh NK, Gupta A, Aggarwal R, Rappuoli R, Johri AK. Verma SK, et al. Front Immunol. 2023 Feb 24;14:1043109. doi: 10.3389/fimmu.2023.1043109. eCollection 2023. Front Immunol. 2023. PMID: 36911719 Free PMC article. Review. - Comparison of Immune Response in Mice Immunized with Recombinant PreS2/S-C18-27 Protein Derived from Hepatitis B Virus with Commercial Vaccine.
Gholami Parizad E, Imani Fooladi AA, Sedighian H, Behzadi E, Valizadeh A, Khosravi A. Gholami Parizad E, et al. Iran J Pathol. 2022 Fall;17(4):448-460. doi: 10.30699/IJP.2022.553785.2896. Epub 2022 Sep 2. Iran J Pathol. 2022. PMID: 36532644 Free PMC article. - Differential Effects of Toll-Like Receptor Signaling on the Activation of Immune Responses in the Upper Respiratory Tract.
Xu M, Li N, Fan X, Zhou Y, Bi S, Shen A, Wang B. Xu M, et al. Microbiol Spectr. 2022 Feb 23;10(1):e0114421. doi: 10.1128/spectrum.01144-21. Epub 2022 Feb 23. Microbiol Spectr. 2022. PMID: 35196817 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous